Pancreatic Cancer Alliance

09/28/2026

SAVE THE DATE! More info very soon!

08/27/2026

FDA approves new pancreatic cancer drug expected to usher in new era of treatment
The therapy, Rasonque from Revolution Medicines, nearly doubled overall survival in a clinical trial. THIS IS A GAME-CHANGER

The Food and Drug Administration on Wednesday approved a life-extending treatment for advanced pancreatic cancer — a medicine made by the biotech company Revolution Medicines that is the first to attack a genetic cause of the aggressive, highly lethal malignancy.

The drug, called daraxonrasib, will be sold under the brand name Rasonque. The FDA’s approval was supported by a practice-changing clinical trial that read out earlier this year. Patients with advanced pancreatic cancer who received Rasonque as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months.

08/18/2026

The Pancreatic Cancer Alliance is very proud of the work we are funding and the people behind it UMass Chan Medical School.

An mRNA immunotherapy developed by scientists at UMass Chan Medical School eliminated pancreatic tumors in about half of treated mice, which remained disease-free for up to a year after treatment ended.

07/21/2026

https://www.sciencealert.com/ai-can-spot-pancreatic-cancer-years-before-diagnosis-study-finds

Pancreatic cancer is on course to be the second-leading cause of cancer-related death in the US by 2030, in part because 85 percent of cases aren't diagnosed until the disease has spread.

06/03/2026

"The results presented at the American Society of Clinical Oncology (ASCO) Annual Meeting for Revolution Medicine’s drug daraxonrasib represent the most significant advance we have ever seen in . For a disease that has long been marked by limited treatment options and often devastating outcomes, seeing a therapy double overall survival in previously treated metastatic pancreatic cancer patients is very encouraging. AND we are told that we will be getting it at UMass Memorial CanUMass Memorial Medical Centery soon. 💜🤞🙏

https://dailynews.ascopubs.org/do/rasolute-302-new-treatment-paradigm-metastatic-pdac-oncogenic-ras-targeting

05/15/2026

Record breaking funding of $25 million this year! $10 million more than ever before! Thank you Pancreatic Cancer Action Network

05/14/2026

We are pleased to acknowledge the exceptional work of Chaitanya Naimesh Parikh, our Pancreatic Cancer Alliance Fellow, for his diligence and commitment.

————————————————————————
Morningside Graduate School of Biomedical Sciences Cancer Biology Program
Announces the PhD Dissertation Defense of

CHAITANYA NAIMESH PARIKH

Development of Multiplexed Cytokine and Antigen mRNA Therapy for Immune-Mediated Tumor Control in Pancreatic Cancer
————————————————————————

04/16/2026

The Hope garden is planted!
Thank you to everyone who purchased pansies 🙏

04/14/2026

THIS!!

A new therapy that targets RAS mutations present in more than 90% of patients with pancreatic adenocarcinoma — the most common type of pancreatic cancer — approximately doubles overall survival according to clinical trial results announced today. 🧪

Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously treated metastatic . For decades, RAS was considered “undruggable,” meaning that there was no effective way to target RAS. These results greatly expand the potential benefit of targeted therapies for patients with pancreatic cancer.

PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, shares, “We are standing at the threshold of groundbreaking treatments for patients with pancreatic cancer. Today’s announcement represents a real opportunity to bring new hope for people facing this disease: hope for more time with family, hope for better quality of life and hope that ongoing and future research may ultimately lead to a cure.” 💜

Next, Revolution Medicines will need to take their data to the U.S. Food and Drug Administration (FDA). If the FDA grants approval for daraxonrasib, it will be made available as a treatment for patients with metastatic pancreatic adenocarcinoma who have been previously treated.

For what you need to know about this news, visit 🔗 http://pcan.at/rjul9sza.

04/10/2026

WHAT A WEEK!
Finally some nice weather to deliver smiles
Hope everyone who wanted them got their order in. We will be delivering all weekend!